Junxian Yu

859 total citations
37 papers, 636 citations indexed

About

Junxian Yu is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Junxian Yu has authored 37 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 14 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Junxian Yu's work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Bioactive Compounds and Antitumor Agents (3 papers). Junxian Yu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Bioactive Compounds and Antitumor Agents (3 papers). Junxian Yu collaborates with scholars based in China, United States and Hong Kong. Junxian Yu's co-authors include Bangwei Cao, Jingshan Shi, Xiuping Chen, Jun Wu, Qin Li, Hang Yin, Fang Geng, Zheng Wang, Manyuan Wang and Kun Shang and has published in prestigious journals such as PLoS ONE, Annals of Oncology and Frontiers in Immunology.

In The Last Decade

Junxian Yu

35 papers receiving 628 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Junxian Yu China 12 256 129 111 84 81 37 636
Mei Zhang China 17 334 1.3× 133 1.0× 120 1.1× 56 0.7× 143 1.8× 54 842
Yifei Dai China 16 340 1.3× 127 1.0× 62 0.6× 62 0.7× 118 1.5× 38 674
Xiaoqing Fan China 18 380 1.5× 154 1.2× 86 0.8× 58 0.7× 109 1.3× 34 750
Yun‐Hee Rhee South Korea 18 346 1.4× 74 0.6× 81 0.7× 137 1.6× 53 0.7× 38 753
Juming Yan China 17 316 1.2× 282 2.2× 93 0.8× 53 0.6× 75 0.9× 27 880
Xiumei Gao China 11 329 1.3× 94 0.7× 67 0.6× 65 0.8× 62 0.8× 20 556
Feifeng Song China 15 320 1.3× 187 1.4× 47 0.4× 59 0.7× 93 1.1× 53 717
Kanamata Reddy United States 15 470 1.8× 163 1.3× 80 0.7× 37 0.4× 65 0.8× 27 706
Zhixia Qiu China 21 448 1.8× 185 1.4× 159 1.4× 155 1.8× 87 1.1× 65 1.1k
Tetsuyuki Takahashi Japan 12 353 1.4× 78 0.6× 189 1.7× 87 1.0× 123 1.5× 32 627

Countries citing papers authored by Junxian Yu

Since Specialization
Citations

This map shows the geographic impact of Junxian Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junxian Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junxian Yu more than expected).

Fields of papers citing papers by Junxian Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junxian Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junxian Yu. The network helps show where Junxian Yu may publish in the future.

Co-authorship network of co-authors of Junxian Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Junxian Yu. A scholar is included among the top collaborators of Junxian Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junxian Yu. Junxian Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wu, Fan, Peng Yuan, Yulan Zeng, et al.. (2024). 101P Circulating tumor DNA minimal residual disease predicts the risk of progression after long-term response to first-line immunotherapy in advanced NSCLC. Annals of Oncology. 35. S254–S254. 1 indexed citations
3.
Feng, Haoran, Junxian Yu, Zhuoqing Xu, et al.. (2024). SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via the inhibition of cystine transport in gastric cancer. EBioMedicine. 109. 105375–105375. 6 indexed citations
4.
Yu, Junxian, Mengdi Chen, Qingqing Sang, et al.. (2024). Super‐enhancer Activates Master Transcription Factor NR3C1 Expression and Promotes 5‐FU Resistance in Gastric Cancer. Advanced Science. 12(7). e2409050–e2409050. 5 indexed citations
5.
Yu, Junxian, Haoran Feng, Qingqing Sang, et al.. (2023). VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer. EBioMedicine. 89. 104451–104451. 15 indexed citations
6.
Ma, Yingjie, Junxian Yu, Xiaoting Ma, et al.. (2023). Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapy. Asia-Pacific Journal of Clinical Oncology. 20(2). 180–187. 2 indexed citations
7.
Li, Fangyuan, Junxian Yu, Tao Pan, et al.. (2023). BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis. Advanced Science. 10(34). e2303091–e2303091. 10 indexed citations
8.
Chen, Wei, Jiayi Chen, Lin Zhang, Sheng Cheng, & Junxian Yu. (2023). Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%. BMC Cancer. 23(1). 791–791. 7 indexed citations
9.
Sang, Qingqing, Wentao Dai, Junxian Yu, et al.. (2022). Identification of prognostic gene expression signatures based on the tumor microenvironment characterization of gastric cancer. Frontiers in Immunology. 13. 983632–983632. 1 indexed citations
10.
Li, Fangyuan, Jianfang Li, Junxian Yu, et al.. (2021). Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data. EBioMedicine. 69. 103436–103436. 16 indexed citations
11.
Zhao, Pengfei, et al.. (2020). <p>Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways</p>. OncoTargets and Therapy. Volume 13. 12325–12339. 4 indexed citations
12.
Liu, Juan, Fandong Meng, Yingying Guan, et al.. (2020). Pharmacokinetics of Bismuth following Oral Administration of Wei Bi Mei in Healthy Chinese Volunteers. Evidence-based Complementary and Alternative Medicine. 2020(1). 2679034–2679034. 2 indexed citations
13.
Liu, Chunna, et al.. (2020). Mechanism and effects of fructose diphosphate on anti-hypoxia fatigue and learning memory ability. Canadian Journal of Physiology and Pharmacology. 98(10). 733–740. 8 indexed citations
14.
Wu, Jun, Junxian Yu, Jing Wang, et al.. (2018). Astragalus polysaccharide enhanced antitumor effects of Apatinib in gastric cancer AGS cells by inhibiting AKT signalling pathway. Biomedicine & Pharmacotherapy. 100. 176–183. 62 indexed citations
15.
Geng, Fang, Zheng Wang, Hang Yin, Junxian Yu, & Bangwei Cao. (2017). Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. Cancer Biotherapy and Radiopharmaceuticals. 32(5). 149–160. 88 indexed citations
16.
Geng, Fang, et al.. (2017). Quantitative analysis of necrostatin-1, a necroptosis inhibitor by LC–MS/MS and the study of its pharmacokinetics and bioavailability. Biomedicine & Pharmacotherapy. 95. 1479–1485. 12 indexed citations
17.
Yu, Junxian, Wei Wang, Dandan Li, et al.. (2016). Anticancer 20(R)-dammarane-3β,12β,20,25-tetrol-loaded polymeric micelles: Preparation, quantification and pharmacokinetics. Journal of Chromatography B. 1022. 13–20. 3 indexed citations
18.
Yu, Junxian, Sukesh Voruganti, Dandan Li, et al.. (2015). Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats. Chinese Journal of Natural Medicines. 13(7). 554–560. 3 indexed citations
19.
Yu, Junxian, Subhasree Nag, & Ruiwen Zhang. (2013). Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents. Current Cancer Drug Targets. 13(5). 596–609. 9 indexed citations
20.
Yan, Hua, et al.. (2008). Silicone Oil in the Surgical Treatment of Traumatic Endophthalmitis. European Journal of Ophthalmology. 18(5). 680–684. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mei Zhang Breakdown of academic impact, for papers by Yifei Dai Breakdown of academic impact, for papers by Xiaoqing Fan Breakdown of academic impact, for papers by Yun‐Hee Rhee Breakdown of academic impact, for papers by Juming Yan Breakdown of academic impact, for papers by Xiumei Gao Breakdown of academic impact, for papers by Feifeng Song Breakdown of academic impact, for papers by Kanamata Reddy Breakdown of academic impact, for papers by Zhixia Qiu Breakdown of academic impact, for papers by Tetsuyuki Takahashi
Rankless by CCL
2026